Synopsis
Reduce vaso-occlusion, organ damage and infection through coordinated surveillance, hydroxycarbamide and preventive care while supporting reproduction, transition, mental health and shared self-management.
- Sickle-cell disease is a lifelong multisystem disorder; absence of recent pain admissions does not exclude progressive renal, pulmonary, neurological, retinal or skeletal injury.
- Every patient should have named specialist follow-up, an individual acute-pain plan, primary-care coordination and a record of genotype, baseline haemoglobin and transfusion antibodies.
- Hydroxycarbamide increases fetal haemoglobin and reduces painful crises and acute chest syndrome; offer it through shared specialist discussion when benefits fit the clinical phenotype.
- Daily adherence, blood-count monitoring and reproductive counselling determine hydroxycarbamide safety and effectiveness more than prescribing the medicine once.
- Functional hyposplenism develops early, so vaccination, antimicrobial prophylaxis where indicated and immediate assessment of fever remain central across adulthood.
- Children require transcranial Doppler surveillance through the national pathway to identify high stroke risk and trigger preventive transfusion decisions.
- Annual review should address blood pressure, urinalysis or albuminuria, kidney and liver function, vision, oxygenation, gallstones, hip or shoulder pain and cardiopulmonary symptoms.
- Ask directly about priapism, menstrual health, contraception, pregnancy plans, fertility, sexual function, sleep, mood, school or work and opioid burden.
- Avoid routine iron unless deficiency is demonstrated; chronic transfusion can cause iron overload and alloimmunisation even when baseline anaemia is substantial.
- Curative allogeneic transplantation and gene-based therapies are specialist options for selected patients; eligibility, long-term uncertainty and equity of access require early referral rather than promises.
Key red flags
New hypoxia, focal neurology, sustained priapism or fever exceeds routine long-term review and activates emergency care.
Investigation priorities
Establish steady-state anaemia, marrow response and treatment toxicity.
Management branches
A person with sickle-cell disease attends scheduled specialist follow-up.
- Reconcile genotype, baseline haematology, admissions, transfusions, antibodies, medicines, vaccines and the individual emergency plan with patient-held information.
- Assess renal, hepatic, cardiopulmonary, neurological, retinal, musculoskeletal, sexual and mental-health domains using age-appropriate tests and symptom triggers.
- Agree a small set of actions, responsible teams and review dates, sharing the plan with primary care, emergency services and maternity or other specialties when relevant.
Key medicines
HydroxycarbamideSpecialists commonly begin at 15 mg/kg orally once daily, reduce the starting dose in renal impairment and titrate in small steps against counts, tolerance and clinical response to a maximum tolerated dose, usually not exceeding 35 mg/kg/day.Myelosuppression requires regular counts and protocol dose holds; discuss pregnancy, contraception, fertility, skin and nail effects and avoid live vaccines or interacting cytotoxic treatment without review.
Phenoxymethylpenicillin prophylaxisUse the current age- and risk-based sickle or asplenia protocol, commonly 250 mg orally twice daily in adults when ongoing prophylaxis is indicated, with an allergy alternative.Missed doses, resistant organisms and non-pneumococcal pathogens remain possible; never let prophylaxis delay emergency assessment and parenteral antibiotics for systemic illness.